Article Text

PDF
▾ Aldesleukin for metastatic renal cell carcinoma?

Abstract

Interleukin 2 (IL2), a protein product of T lymphocytes, promotes the development of lymphokine-activated killer (LAK) cells, which can lyse tumour cells.1 Aldesleukin (Proleukin – EuroCetus), a recombinant human IL2, has recently been marketed for the treatment of patients with metastatic renal cell carcinoma.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.